Royalty Pharma plc Net Income (Loss) Attributable to Noncontrolling Interest
Royalty Pharma plc (RPRX) reported Net Income (Loss) Attributable to Noncontrolling Interest of $63.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-05
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was $63.60M, a 5.20% increase year-over-year.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $173.57M, a 11.03% decline year-over-year.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $141.71M, a 12.34% increase year-over-year.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $155.99M, a 40.54% decline year-over-year.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for fiscal 2025 was $553.25M, a 17.26% increase from fiscal 2024.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for fiscal 2024 was $471.83M, a 16.53% decline from fiscal 2023.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for fiscal 2023 was $565.25M, a 201.90% increase from fiscal 2022.
- Royalty Pharma plc net income (loss) attributable to noncontrolling interest for fiscal 2022 was $187.23M, a 69.87% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.60M 10-Q · filed 2026-08-05 | $237.17M 10-Q · filed 2026-08-05 | $378.88M derived: sum of 3 quarters · filed 2026-08-05 | $534.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $173.57M 10-Q · filed 2026-05-06 | $315.27M derived: sum of 2 quarters · filed 2026-05-06 | $471.27M derived: sum of 3 quarters · filed 2026-05-06 | $531.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $141.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $297.70M derived: sum of 2 quarters · filed 2026-02-11 | $358.16M derived: sum of 3 quarters · filed 2026-08-05 | $553.25M 10-K · filed 2026-02-11 |
| 2025-09-30 | $155.99M 10-Q · filed 2025-11-05 | $216.45M derived: sum of 2 quarters · filed 2026-08-05 | $411.54M 10-Q · filed 2025-11-05 | $537.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $60.46M 10-Q · filed 2026-08-05 | $255.54M 10-Q · filed 2026-08-05 | $381.68M derived: sum of 3 quarters · filed 2026-08-05 | $644.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $195.08M 10-Q · filed 2026-05-06 | $321.22M derived: sum of 2 quarters · filed 2026-05-06 | $583.59M derived: sum of 3 quarters · filed 2026-05-06 | $675.97M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $126.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $388.51M derived: sum of 2 quarters · filed 2026-02-11 | $480.88M derived: sum of 3 quarters · filed 2026-02-11 | $471.83M 10-K · filed 2026-02-11 |
| 2024-09-30 | $262.37M 10-Q · filed 2025-11-05 | $354.74M derived: sum of 2 quarters · filed 2025-11-05 | $345.69M 10-Q · filed 2025-11-05 | $568.94M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $92.37M 10-Q · filed 2025-08-06 | $83.32M 10-Q · filed 2025-08-06 | $306.57M derived: sum of 3 quarters · filed 2026-02-11 | $356.53M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$9.05M 10-Q · filed 2025-05-08 | $214.19M derived: sum of 2 quarters · filed 2026-02-11 | $264.16M derived: sum of 3 quarters · filed 2026-02-11 | $387.87M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $223.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $273.21M derived: sum of 2 quarters · filed 2026-02-11 | $396.92M derived: sum of 3 quarters · filed 2026-02-11 | $565.25M 10-K · filed 2026-02-11 |
| 2023-09-30 | $49.96M 10-Q · filed 2024-11-06 | $173.67M derived: sum of 2 quarters · filed 2024-11-06 | $342.01M 10-Q · filed 2024-11-06 | $188.06M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $123.71M 10-Q · filed 2024-08-08 | $292.05M 10-Q · filed 2024-08-08 | $138.10M derived: sum of 3 quarters · filed 2025-02-12 | $215.86M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $168.33M 10-Q · filed 2024-05-09 | $14.39M derived: sum of 2 quarters · filed 2025-02-12 | $92.15M derived: sum of 3 quarters · filed 2025-02-12 | $279.24M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$153.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$76.18M derived: sum of 2 quarters · filed 2025-02-12 | $110.91M derived: sum of 3 quarters · filed 2025-02-12 | $187.23M 10-K · filed 2025-02-12 |
| 2022-09-30 | $77.76M 10-Q · filed 2023-11-08 | $264.86M derived: sum of 2 quarters · filed 2023-11-08 | $341.18M 10-Q · filed 2023-11-08 | $386.94M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $187.09M 10-Q · filed 2023-08-08 | $263.42M 10-Q · filed 2023-08-08 | $309.18M derived: sum of 3 quarters · filed 2024-02-15 | $429.05M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $76.32M 10-Q · filed 2023-05-09 | $122.09M derived: sum of 2 quarters · filed 2024-02-15 | $241.96M derived: sum of 3 quarters · filed 2024-02-15 | $607.93M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $45.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $165.63M derived: sum of 2 quarters · filed 2024-02-15 | $531.61M derived: sum of 3 quarters · filed 2024-02-15 | $621.47M 10-K · filed 2024-02-15 |
| 2021-09-30 | $119.87M 10-Q · filed 2022-11-08 | $485.85M derived: sum of 2 quarters · filed 2022-11-08 | $575.71M 10-Q · filed 2022-11-08 | $771.24M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $365.98M 10-Q · filed 2022-08-04 | $455.84M 10-Q · filed 2022-08-04 | $651.37M derived: sum of 3 quarters · filed 2023-02-15 | $985.00M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $89.86M 10-Q · filed 2022-05-05 | $285.39M derived: sum of 2 quarters · filed 2023-02-15 | $619.02M derived: sum of 3 quarters · filed 2023-02-15 | $778.92M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $195.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $529.16M derived: sum of 2 quarters · filed 2023-02-15 | $689.06M derived: sum of 3 quarters · filed 2023-02-15 | $726.91M 10-K · filed 2023-02-15 |
| 2020-09-30 | $333.62M 10-Q · filed 2021-11-10 | $493.52M derived: sum of 2 quarters · filed 2021-11-10 | $531.38M 10-Q · filed 2021-11-10 | $557.51M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $159.90M 10-Q · filed 2021-08-11 | $197.76M 10-Q · filed 2021-08-11 | $223.89M derived: sum of 3 quarters · filed 2022-02-15 | $254.94M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $37.86M 10-Q · filed 2021-05-11 | $63.99M derived: sum of 2 quarters · filed 2022-02-15 | $95.03M derived: sum of 3 quarters · filed 2022-02-15 | $122.09M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $57.18M derived: sum of 2 quarters · filed 2022-02-15 | $84.23M derived: sum of 3 quarters · filed 2022-02-15 | $112.88M 10-K · filed 2022-02-15 |
| 2019-09-30 | $31.05M 10-Q · filed 2020-11-12 | $58.10M derived: sum of 2 quarters · filed 2020-11-12 | $86.75M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $27.06M 10-Q · filed 2020-08-12 | $55.71M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $140.13M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |